<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1920_S09_C00FM_pi-xvi_8P</title>
		<link href="BCSC1920_S09_C00FM_pi-xvi_8P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1920_S09_C00FM_pi-xvi_8P" lang="en-US">
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer000" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C00FM_pi-xvi_8P-web-resources/image/AAO_med_full_clr_c_cmyk_reg.png" alt="" />
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="BCSC1920_S09_C00FM_pi-xvi_8P-web-resources/image/AAO_tag_gray_c_cmyk_reg.png" alt="" />
			</div>
		</div>
		<div id="_idContainer002" class="Basic-Text-Frame">
			<p class="NEW-Title"><span class="CharOverride-1">Uveitis and Ocular <br />Inflammation</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer003" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer004" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer005" class="Basic-Text-Frame">
			</div>
		</div>
		<div id="_idContainer006" class="Basic-Graphics-Frame _idGenObjectStyleOverride-1">
			<p class="BCSC-Spelled-Out---Cover ParaOverride-1"><span class="CharOverride-2"> </span><span class="CharOverride-2">BCSC</span></p>
			<p class="BCSC-Spelled-Out---Cover"><span class="CharOverride-3"> </span><span class="CharOverride-4">Basic and Clinical</span></p>
			<p class="BCSC-Spelled-Out---Cover"><span class="CharOverride-4"> </span><span class="CharOverride-4">Science Course</span><span class="CharOverride-5">™</span></p>
		</div>
		<div id="_idContainer007" class="Basic-Text-Frame">
			<p class="Year---Cover ParaOverride-2"><span class="CharOverride-6">2019–2020</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="data:image/jpg;base64,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" alt="" />
			</div>
		</div>
		<div id="_idContainer009" class="Basic-Text-Frame">
			<p class="Basic-Paragraph ParaOverride-3"><span class="CharOverride-7">9</span></p>
		</div>
		<div id="_idContainer010" class="Basic-Text-Frame">
			<p class="fm-tp--pub-rev-date-"><span class="CharOverride-8">Published after collaborative <br />review with the European Board <br />of Ophthalmology subcommittee</span></p>
		</div>
		<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-copyright-cme-text ParaOverride-4">The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.</p>
			<p class="fm-only_fm-copyright-cme-text ParaOverride-5">The American Academy of Ophthalmology designates this enduring material for a maximum of 10 <span class="CharOverride-9">AMA PRA Category 1 Credits</span><span class="CharOverride-10">™</span>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>
			<p class="fm-only_fm-copyright-text">CME expiration date: June&#160;1, 2022. <span class="CharOverride-9">AMA PRA Category 1 Credits</span><span class="CharOverride-11">™</span> may be claimed only once between June 1, 2019, and the expiration date.</p>
			<p class="fm-only_fm-copyright-text">BCSC<span class="CharOverride-10">®</span> volumes are designed to increase the physician’s ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.</p>
			<p class="fm-only_fm-copyright-text">To claim <span class="CharOverride-9">AMA PRA Category 1 Credits</span><span class="CharOverride-10">™</span> upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 9 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.</p>
			<p class="fm-only_fm-copyright-text">The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician’s own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers’ package inserts or other independent sources, and considered in light of the patient’s condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. <span class="CharOverride-12">The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law.</span> The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.</p>
			<p class="fm-only_fm-copyright-text ParaOverride-6">All trademarks, trade names, logos, brand names, and service marks of the American Academy of Ophthalmology (AAO), whether registered or unregistered, are the property of AAO and are protected by US and international trademark laws. These trademarks include AAO; AAOE; AMERICAN ACADEMY OF OPHTHALMOLOGY; BASIC AND CLINICAL SCIENCE COURSE; BCSC; EYENET; EYEWIKI; FOCAL POINTS; FOCUS DESIGN (logo shown on cover); IRIS; ISRS; OKAP; ONE NETWORK; OPHTHALMOLOGY; OPHTHALMOLOGY GLAUCOMA; OPHTHALMOLOGY RETINA; PREFERRED PRACTICE PATTERN; PROTECTING SIGHT. EMPOWERING LIVES; and THE OPHTHALMIC NEWS &amp; EDUCATION NETWORK.</p>
			<p class="fm-only_fm-copyright-text ParaOverride-7">Cover image: Large mutton-fat keratic precipitates in a patient with sarcoidosis. <span class="italic">(Courtesy of Debra Goldstein, MD.)</span></p>
			<p class="fm-only_fm-title _idGenParaOverride-1">Basic and Clinical Science Course</p>
			<p class="fm-only_fm-contributors-text">Louis B. Cantor, MD, Indianapolis, Indiana, <span class="CharOverride-9">Senior Secretary for Clinical Education</span></p>
			<p class="fm-only_fm-contributors-text">Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, <span class="CharOverride-9">Secretary for Lifelong Learning and Assessment</span></p>
			<p class="fm-only_fm-contributors-text">Colin A. McCannel, MD, Los Angeles, California,<span class="CharOverride-9"> BCSC Course Chair</span></p>
			<p class="fm-only_fm-h1 ParaOverride-8">Section 9</p>
			<p class="fm-only_fm-h2 ParaOverride-9">Faculty for the Major Revision</p>
			<p class="fm-only_fm-contributors-text">H. Nida Sen, MD, MHSc, <span class="italic">Chair</span>, Bethesda, Maryland</p>
			<p class="fm-only_fm-contributors-text">Thomas A. Albini, MD, Miami, Florida</p>
			<p class="fm-only_fm-contributors-text">Bryn M. Burkholder, MD, Baltimore, Maryland</p>
			<p class="fm-only_fm-contributors-text">Sam S. Dahr, MD, MS, Oklahoma City, Oklahoma</p>
			<p class="fm-only_fm-contributors-text">Emilio M. Dodds, MD, Buenos Aires, Argentina</p>
			<p class="fm-only_fm-contributors-text">Thellea K. Leveque, MD, MPH, Seattle, Washington</p>
			<p class="fm-only_fm-contributors-text">Wendy M. Smith, MD, Rochester, Minnesota</p>
			<p class="fm-only_fm-contributors-text">Daniel V. Vasconcelos-Santos, MD, PhD, Belo Horizonte, Brazil</p>
			<p class="fm-only_fm-disclaimers ParaOverride-10">The Academy wishes to acknowledge the American Uveitis Society (AUS) for recommending faculty members to the BCSC Section 9 committee.</p>
			<p class="fm-only_fm-disclaimers ParaOverride-11">The Academy also wishes to acknowledge the following committees for review of this edition: </p>
			<p class="fm-only_fm-disclaimers ParaOverride-11"><span class="italic">Committee on Aging:</span> Kelly L. Larkin, MD, Houston, Texas</p>
			<p class="fm-only_fm-disclaimers ParaOverride-11"><span class="italic">Vision Rehabilitation Committee:</span> William M. McLaughlin Jr, DO, Allentown, Pennsylvania</p>
			<p class="fm-only_fm-disclaimers ParaOverride-11"><span class="italic">Practicing Ophthalmologists Advisory Committee for Education:</span> Michelle S. Ying, MD, MSPH, <span class="italic">primary reviewer,</span> Ladson, South Carolina; Bradley D. Fouraker, MD, <span class="italic">Chair,</span> Tampa, Florida; Alice Bashinsky, MD, Asheville, North Carolina; David J. Browning, MD, PhD, Charlotte, North Carolina; Cynthia S. Chiu, MD, Oakland, California; Steven J. Grosser, MD, Golden Valley, Minnesota; Stephen R. Klapper, MD, Carmel, Indiana; Troy M. Tanji, MD, Waipahu, Hawaii</p>
			<p class="fm-only_fm-disclaimers ParaOverride-11"><span class="italic">Pan American Association of Ophthalmology BCSC 9 Review Committee:</span> Emilio M. Dodds, MD, <span class="italic">Chair,</span> Buenos Aires, Argentina; Enzo Castiglione, MD, Santiago, Chile; Cristóbal A. Couto, MD, Buenos Aires, Argentina; Alejandra de la Torre, MD, PhD, Bogotá, Colombia; Ariel Schlaen, MD, Buenos Aires, Argentina; Carlos D. Siverio, MD, Lima, Peru; Daniel V. Vasconcelos-Santos, MD, PhD, Belo Horizonte, Brazil</p>
			<p class="fm-only_fm-disclaimers">The Academy also wishes to acknowledge the following committee for assistance in developing Study Questions and Answers for this BCSC Section: </p>
			<p class="fm-only_fm-disclaimers"><span class="italic">Self-Assessment Committee:</span> John A. Gonzales, MD, San Francisco, California; Michael A. Kapamajian, MD, Los Angeles, California; Humeyra H. Karacal, MD, St Louis, Missouri</p>
			<p class="fm-only_fm-disclaimers ParaOverride-12"><img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" /></p>
			<p class="fm-only_fm-disclaimers ParaOverride-13"><span class="italic">European Board of Ophthalmology:</span> Peter J. Ringens, MD, PhD, <span class="italic">EBO-BCSC Program Liaison,</span> Maastricht, Netherlands; Joke H. De Boer, MD, PhD, <span class="italic">EBO Chair for BCSC Section 9,</span> Utrecht, Netherlands</p>
			<p class="fm-only_fm-h2">Financial Disclosures</p>
			<p class="fm-only_fm-disclaimers ParaOverride-13">Academy staff members who contributed to the development of this product state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.</p>
			<p class="fm-only_fm-disclaimers">The authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had the following financial relationships:<span class="CharOverride-13">*</span></p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Albini: Abbvie (C), Allergan (C), Bausch + Lomb (C), Clearside Biomedical (C), Genentech (C), Mallinckrodt Pharmaceuticals (C), Novartis Alcon Pharmaceuticals (C), pSivida (C), Santen (C)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Browning: Aerpio Therapeutics (S), Alcon Laboratories (S), Alimera Sciences (C), Emmes (S), Genentech (S), Novartis Pharmaceuticals (S), Ohr Pharmaceutical (S), <br />Pfizer (S), Regeneron Pharmaceuticals (S), Springer (P), Zeiss (O)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Couto: Allergan (L)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr de la Torre: Abbvie (C, L)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Dahr: Novo Nordisk (C)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr De Boer: Abbvie (C, L)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Fouraker: Addition Technology (C, L), Alcon Laboratories (C, L), <br />OASIS Medical (C, L)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Grosser: InjectSense (O), Ivantis (O)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Klapper: AdOM Advanced Optical Technologies (O)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Larkin: Quark Pharmaceuticals (C)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Schlaen: Abbvie (C, L)</p>
			<p class="fm-only_fm-disclaimers ParaOverride-2">Dr Smith: Inotek Pharmaceuticals (C)</p>
			<p class="fm-only_fm-disclaimers">The other authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.</p>
			<p class="fm-only_fm-disclaimers-footnote"><span class="CharOverride-13">*</span>C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/&#173;stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation</p>
			<p class="fm-only_fm-h2 ParaOverride-14">Recent Past Faculty</p>
			<p class="fm-only_fm-contributors-text">Nisha Acharya, MD </p>
			<p class="fm-only_fm-contributors-text">Ralph D. Levinson, MD</p>
			<p class="fm-only_fm-contributors-text">P. Kumar Rao, MD</p>
			<p class="fm-only_fm-contributors-text">Russell W. Read, MD, PhD</p>
			<p class="fm-only_fm-contributors-text">Jonathan D. Walker, MD</p>
			<p class="fm-only_fm-disclaimers">In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.</p>
			<p class="fm-only_fm-h2">American Academy of Ophthalmology Staff</p>
			<p class="fm-only_fm-contributors-text">Dale E. Fajardo, EdD, MBA, <span class="italic">Vice President, Education</span></p>
			<p class="fm-only_fm-contributors-text">Beth Wilson, <span class="italic">Director, Continuing Professional Development</span></p>
			<p class="fm-only_fm-contributors-text">Ann McGuire, <span class="italic">Acquisitions and Development Manager</span></p>
			<p class="fm-only_fm-contributors-text">Stephanie Tanaka, <span class="italic">Publications Manager</span></p>
			<p class="fm-only_fm-contributors-text">Susan Malloy, <span class="italic">Acquisitions Editor and Program Manager</span></p>
			<p class="fm-only_fm-contributors-text">Jasmine Chen, <span class="italic">Manager of E-Learning</span></p>
			<p class="fm-only_fm-contributors-text">Beth Collins, <span class="italic">Medical Editor</span></p>
			<p class="fm-only_fm-contributors-text">Eric Gerdes, <span class="italic">Interactive Designer</span></p>
			<p class="fm-only_fm-contributors-text">Naomi Ruiz, <span class="italic">Publications Specialist</span></p>
			<p class="fm-only_fm-contributors-text _idGenParaOverride-1">Debra Marchi, <span class="italic">Permissions Assistant</span></p>
			<p class="fm-only_fm-title _idGenParaOverride-1">General Introduction</p>
			<p class="body-text--no-indent-">The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.</p>
			<p class="body-text">The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.</p>
			<p class="fm-only_fm-h2">Organization of the Course</p>
			<p class="body-text--no-indent-">The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:</p>
			<p class="fm-only_fm-numbered-list-first">&#9;1&#9;Update on General Medicine</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;2&#9;Fundamentals and Principles of Ophthalmology</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;3&#9;Clinical Optics</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;4&#9;Ophthalmic Pathology and Intraocular Tumors</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;5&#9;Neuro-Ophthalmology</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;6&#9;Pediatric Ophthalmology and Strabismus</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;7&#9;Oculofacial Plastic and Orbital Surgery</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;8&#9;External Disease and Cornea</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;9&#9;Uveitis and Ocular Inflammation</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;10&#9;Glaucoma</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;11&#9;Lens and Cataract</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;12&#9;Retina and Vitreous</p>
			<p class="fm-only_fm-numbered-list-last">&#9;13&#9;Refractive Surgery</p>
			<p class="body-text--no-indent-">In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.</p>
			<p class="fm-only_fm-h2">References</p>
			<p class="body-text--no-indent-">Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book. These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.</p>
			<p class="fm-only_fm-h2">Multimedia</p>
			<p class="body-text--no-indent-">This edition of Section 9, <span class="italic">Uveitis and Ocular Inflammation,</span> includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty to present important topics that are best delivered visually. This edition also includes an interactive feature, or “activity,” developed by members of the BCSC faculty. Both the videos and the activity are available to readers of the print and electronic versions of Section 9 (www.aao .org/bcscvideo_section09) and (www.aao.org/bcscactivity_section09). Mobile-device users can scan the QR codes below (a QR-code reader must already be installed on the device) to access the videos and activity.</p>
			<p class="body-text--no-indent- ParaOverride-15">&#9;<img class="_idGenObjectAttribute-3" src="BCSC1920_S09_C00FM_pi-xvi_8P-web-resources/image/qrcode_BCSC2019_S09_Video-landing-page.png" alt="" />&#9;<img class="_idGenObjectAttribute-3" src="BCSC1920_S09_C00FM_pi-xvi_8P-web-resources/image/1.png" alt="" />&#9;</p>
			<p class="fm-only_fm-h2 ParaOverride-16">Self-Assessment and CME Credit</p>
			<p class="body-text--no-indent-">Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page xv. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.</p>
			<p class="body-text">This Section of the BCSC has been approved by the American Board of Ophthal&#173;mology as a Maintenance of Certification Part II self-assessment CME activity.</p>
			<p class="fm-only_fm-h2">Conclusion</p>
			<p class="body-text--no-indent-">The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.</p>
			<p class="body-text">The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.</p>
			<p class="body-text">The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.</p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer015" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />
			</div>
		</div>
		<div id="_idContainer016" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-copyright1--pub-info-1">Copyright © 2019 American Academy of Ophthalmology. All rights reserved. No part of this publication may be reproduced without written permission.</p>
			<p class="fm-only_fm-copyright-text">Printed in China.</p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer017" class="_idGenObjectStyleOverride-3">
			</div>
		</div>
		<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-copyright2--pub-info-">American Academy of Ophthalmology</p>
			<p class="fm-only_fm-copyright2--pub-info-">655 Beach Street</p>
			<p class="fm-only_fm-copyright2--pub-info-">Box 7424</p>
			<p class="fm-only_fm-copyright2--pub-info-">San Francisco, CA 94120-7424</p>
		</div>
		<div id="_idContainer019" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-title _idGenParaOverride-1">Contents</p>
			<p class="fm-only_fm-toc-fm1">General Introduction&#9;xiii</p>
			<p class="fm-only_fm-toc-fm1">Objectives<span class="fm-toc--leader-dots-">&#9;</span>xv</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">1</span></a><span class="fm-toc02--num-">&#9;</span><a href="">Basic Concepts in Immunology: <br />Effector Cells and the Innate Immune Response<span class="fm-toc--leader-dots-">&#9;</span></a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Definitions&#9;</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Components of the Immune System&#9;</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Leukocytes&#9;2</a></p>
			<p class="fm-only_fm-toc03"><a href="">Overview of the Innate Immune System&#9;</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">Immunity Versus Inflammation&#9;</a>6</p>
			<p class="fm-only_fm-toc03"><a href="">Triggers of Innate Immunity&#9;</a>6</p>
			<p class="fm-only_fm-toc04"><a href="">Bacteria-&#173;Derived Molecules That Trigger Innate Immunity&#9;</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Other Triggers or Modulators of Innate Immunity&#9;1</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Innate Mechanisms for the Recruitment and Activation <br />of Neutrophils&#9;1</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Innate Mechanisms for the Recruitment and Activation <br />of Macrophages&#9;1</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Phagocyte-&#173;Killing Mechanisms&#9;1</a>6</p>
			<p class="fm-only_fm-toc04"><a href="">Reactive Nitrogen Products&#9;1</a>6</p>
			<p class="fm-only_fm-toc03"><a href="">Mediator Systems That Amplify Immune Responses&#9;1</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Plasma-&#173;Derived Enzyme Systems&#9;1</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Lipid Mediators&#9;</a>19</p>
			<p class="fm-only_fm-toc04"><a href="">Cytokines&#9;2</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Neutrophil-&#173;Derived Granule Products&#9;2</a>5</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">2</span></a><span class="fm-toc02--num-">&#9;</span><a href="">Immunization and Adaptive Immunity: <br />The Immune Response Arc and Immune Effectors<span class="fm-toc--leader-dots-">&#9;</span></a>27</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;2</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Definitions&#9;2</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Phases of the Immune Response Arc&#9;</a>29</p>
			<p class="fm-only_fm-toc04">Afferent Phase&#9;29</p>
			<p class="fm-only_fm-toc04"><a href="">Pro&#173;cessing Phase&#9;3</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Effector Phase&#9;3</a>6</p>
			<p class="fm-only_fm-toc03"><a href="">Immune Response Arc and Primary or Secondary Immune Response&#9;3</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Differences Between Primary and Secondary Responses&#9;3</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Homing&#9;</a>38</p>
			<p class="fm-only_fm-toc03"><a href="">Effector Responses of Adaptive Immunity&#9;</a>38</p>
			<p class="fm-only_fm-toc04"><a href="">Antibody-&#173;Mediated Immune Effector Responses&#9;</a>39</p>
			<p class="fm-only_fm-toc04"><a href="">Lymphocyte-&#173;Mediated Effector Responses&#9;4</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Combined Antibody and Cellular Effector Mechanisms&#9;4</a>7</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">3</span></a><span class="fm-toc02--num-">&#9;</span><a href="">Ocular Immune Responses<span class="fm-toc--leader-dots-">&#9;</span>5</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;5</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Regional Immunity and Immunologic Microenvironments&#9;5</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Immune Responses of the Conjunctiva&#9;5</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Features of the Immunologic Microenvironment&#9;53</a></p>
			<p class="fm-only_fm-toc04"><a href="">Immunoregulatory Systems&#9;5</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Immune Responses of the Cornea&#9;5</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Features of the Immunologic Microenvironment&#9;54</a></p>
			<p class="fm-only_fm-toc04"><a href="">Immunoregulatory Systems&#9;5</a>4</p>
			<p class="fm-only_fm-toc03"><a href="">Immune Responses of the Anterior Chamber, Anterior Uvea, and Vitreous&#9;5</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">Features of the Immunologic Microenvironment&#9;55</a></p>
			<p class="fm-only_fm-toc04"><a href="">Immunoregulatory Systems&#9;5</a>6</p>
			<p class="fm-only_fm-toc03"><a href="">Immune Responses of the Ret&#173;ina, Ret&#173;i&#173;nal Pigment Epithelium, <br />Choriocapillaris, and Choroid&#9;5</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Features of the Immunologic Microenvironment&#9;57</a></p>
			<p class="fm-only_fm-toc04">Immunoregulatory Systems&#9;59</p>
			<p class="fm-only_fm-toc02 ParaOverride-17"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">4</span></a><span class="fm-toc02--num-">&#9;</span><a href="">Special Topics in Ocular Immunology<span class="fm-toc--leader-dots-">&#9;</span>6</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;6</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Animal Models of &#173;Human Uveitis&#9;6</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Experimental Autoimmune Uveoretinitis&#9;6</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Endotoxin-&#173;Induced Uveitis&#9;6</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Equine Recurrent Uveitis&#9;6</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Autoimmune Regulator–&#173;Deficient Mice&#9;6</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Interphotoreceptor Retinoid-&#173;Binding Protein–&#173;Specific <br />T-Cell Receptor Transgenic Mice&#9;6</a>2</p>
			<p class="fm-only_fm-toc03"><a href="">HLA Associations and Disease&#9;6</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Normal Function of HLA Molecules&#9;6</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Allelic Variation&#9;6</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Disease Associations&#9;6</a>4</p>
			<p class="fm-only_fm-toc02 ParaOverride-17"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">5</span></a><span class="fm-toc02--num-">&#9;</span>Diagnostic Considerations in&#160;Uveitis<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>67</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;6</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Overview&#9;6</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Epidemiology&#9;</a>68</p>
			<p class="fm-only_fm-toc03"><a href="">Classification of Uveitis&#9;</a>68</p>
			<p class="fm-only_fm-toc04"><a href="">Anatomical Classification&#9;7</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Classification by Clinical Features&#9;7</a>5</p>
			<p class="fm-only_fm-toc03"><a href="">Symptoms of Uveitis&#9;7</a>6</p>
			<p class="fm-only_fm-toc03"><a href="">Signs of Uveitis&#9;7</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Anterior Segment&#9;7</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Intermediate Segment&#9;8</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Posterior Segment&#9;8</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Review of the Patient’s Health and Other Associated &#173;Factors&#9;8</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Differential Diagnosis of Uveitis&#9;8</a>4</p>
			<p class="fm-only_fm-toc03"><a href="">Ancillary Testing&#9;8</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Ophthalmic Imaging and Functional Tests&#9;8</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Fluid and Tissue Sampling&#9;9</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Cytology and Pathology&#9;9</a>1</p>
			<p class="fm-only_fm-toc02 ParaOverride-17"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">6</span></a><span class="fm-toc02--num-">&#9;</span>Therapy for Uveitis<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>93</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;9</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Medical Management of Uveitis&#9;9</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Corticosteroids&#9;9</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Systemic Immunomodulatory Therapy&#9;10</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Nonbiologic Immunomodulatory Therapy&#9;10</a>6</p>
			<p class="fm-only_fm-toc04"><a href="">Tumor Necrosis &#173;Factor Inhibitors&#9;11</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Other Biologic Agents&#9;11</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Other Therapeutic Agents&#9;11</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Surgical Management of Uveitis&#9;11</a>3</p>
			<p class="fm-only_fm-toc02 ParaOverride-17"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">7</span></a><span class="fm-toc02--num-">&#9;</span>Scleritis<a href=""><span class="fm-toc--leader-dots-">&#9;</span>1</a>15</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;11</a>5</p>
			<p class="fm-only_fm-toc03"><a href="">Introduction&#9;11</a>5</p>
			<p class="fm-only_fm-toc03"><a href="">Classification of Scleritis&#9;11</a>5</p>
			<p class="fm-only_fm-toc03"><a href="">Pathophysiology&#9;11</a>6</p>
			<p class="fm-only_fm-toc03"><a href="">Epidemiology&#9;11</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Clinical Pre&#173;sen&#173;ta&#173;tion&#9;11</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Diffuse Anterior Scleritis&#9;1</a>18</p>
			<p class="fm-only_fm-toc04"><a href="">Nodular Anterior Scleritis&#9;1</a>18</p>
			<p class="fm-only_fm-toc04"><a href="">Necrotizing Scleritis&#9;1</a>19</p>
			<p class="fm-only_fm-toc04"><a href="">Posterior Scleritis&#9;12</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Infectious Scleritis&#9;12</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Diagnosis&#9;12</a>4</p>
			<p class="fm-only_fm-toc03"><a href="">Treatment&#9;12</a>6</p>
			<p class="fm-only_fm-toc04"><a href="">Systemic Treatment&#9;12</a>6</p>
			<p class="fm-only_fm-toc04"><a href="">Surgical Treatment&#9;12</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Prognosis&#9;12</a>7</p>
			<p class="fm-only_fm-toc02 ParaOverride-17"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">8</span></a><span class="fm-toc02--num-">&#9;</span>Noninfectious Anterior and&#160;Intermediate Uveitis<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>129</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;1</a>29</p>
			<p class="fm-only_fm-toc03"><a href="">Anterior Uveitis&#9;1</a>29</p>
			<p class="fm-only_fm-toc04"><a href="">Acute Nongranulomatous Anterior Uveitis&#9;13</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Chronic Anterior Uveitis&#9;14</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Intermediate Uveitis&#9;14</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Pars Planitis&#9;14</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Multiple Sclerosis&#9;15</a>1</p>
			<p class="fm-only_fm-toc02 ParaOverride-17"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">9</span></a><span class="fm-toc02--num-">&#9;</span>Posterior Uveitis and Panuveitis<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>153</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;15</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Posterior Uveitis&#9;15</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Collagen Vascular Diseases&#9;15</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Susac Syndrome&#9;16</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Inflammatory Chorioretinopathies of Unknown Etiology&#9;16</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Panuveitis&#9;19</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Sarcoidosis&#9;19</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Sympathetic Ophthalmia&#9;</a>199</p>
			<p class="fm-only_fm-toc04"><a href="">Vogt-&#173;Koyanagi-&#173;Harada Syndrome&#9;20</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Beh<span class="h2_accent">ç</span>et Disease&#9;21</a>1</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">10</span></a><span class="fm-toc02--num-">&#9;</span>Infectious Uveitis: Bacterial &#173;Causes<a href=""><span class="fm-toc--leader-dots-">&#9;</span>2</a>19</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;2</a>19</p>
			<p class="fm-only_fm-toc03"><a href="">Syphilis&#9;2</a>19</p>
			<p class="fm-only_fm-toc04"><a href="">Congenital Syphilis&#9;22</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Acquired Syphilis&#9;22</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Involvement&#9;22</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;22</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;22</a>5</p>
			<p class="fm-only_fm-toc03"><a href="">Lyme Disease&#9;22</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Clinical Features&#9;22</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Involvement&#9;2</a>29</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;23</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;23</a>0</p>
			<p class="fm-only_fm-toc03"><a href="">Leptospirosis&#9;23</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Involvement&#9;23</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;23</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;23</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Ocular Nocardiosis&#9;23</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Involvement&#9;23</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;23</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;23</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Tuberculosis&#9;23</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Involvement&#9;23</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;2</a>38</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;2</a>39</p>
			<p class="fm-only_fm-toc03"><a href="">Ocular Bartonellosis&#9;24</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Involvement&#9;24</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;24</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;24</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Whipple Disease&#9;24</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Involvement&#9;24</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;24</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;24</a>5</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">11</span></a><span class="fm-toc02--num-">&#9;</span>Infectious Uveitis: Nonbacterial &#173;Causes<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>247</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;24</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Viral Uveitis&#9;24</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Herpesviridae &#173;Family&#9;247</a></p>
			<p class="fm-only_fm-toc04"><a href="">Rubella&#9;2</a>58</p>
			<p class="fm-only_fm-toc04"><a href="">Lymphocytic Choriomeningitis Virus&#9;26</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Mumps&#9;26</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Measles (Rubeola)&#9;26</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">West Nile Virus&#9;26</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Rift Valley Fever&#9;26</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">&#173;Human T-&#173;Lymphotropic Virus Type 1&#9;26</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">Dengue Fever&#9;26</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Chikungunya Fever&#9;2</a>68</p>
			<p class="fm-only_fm-toc04"><a href="">Zika Virus&#9;2</a>69</p>
			<p class="fm-only_fm-toc04"><a href="">Ebola Virus&#9;27</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Other Viral Diseases&#9;27</a>2</p>
			<p class="fm-only_fm-toc03"><a href="">Fungal Uveitis&#9;27</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Histoplasmosis Syndrome&#9;272</a></p>
			<p class="fm-only_fm-toc03"><a href="">Protozoal Uveitis&#9;27</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">Toxoplasmosis&#9;275</a></p>
			<p class="fm-only_fm-toc04"><a href="">Toxocariasis&#9;28</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Cysticercosis&#9;28</a>5</p>
			<p class="fm-only_fm-toc04"><a href="">Diffuse Unilateral Subacute Neuroretinitis&#9;28</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Onchocerciasis (River Blindness)&#9;2</a>89</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">1</span></a><span class="fm-toc02--num-">2&#9;</span>Endophthalmitis<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>291</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;29</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Chronic Postoperative Endophthalmitis&#9;29</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Clinical Findings&#9;29</a>2</p>
			<p class="fm-only_fm-toc04"><a href="">Diagnosis&#9;29</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;29</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Endogenous Endophthalmitis&#9;29</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Endogenous Bacterial Endophthalmitis&#9;294</a></p>
			<p class="fm-only_fm-toc04"><a href="">Endogenous Fungal Endophthalmitis&#9;29</a>5</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">1</span></a><span class="fm-toc02--num-">3&#9;</span>Masquerade Syndromes<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>303</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;30</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Neoplastic Masquerade Syndromes&#9;30</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Primary Vitreoret&#173;i&#173;nal Lymphoma&#9;30</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Neoplastic Masquerade Syndromes Secondary to Systemic <br />Lymphoma&#9;30</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Neoplastic Masquerade Syndromes Secondary to Leukemia&#9;3</a>08</p>
			<p class="fm-only_fm-toc04"><a href="">Neoplastic Masquerade Syndromes Secondary to Uveal Lymphoid Proliferations&#9;30</a>8</p>
			<p class="fm-only_fm-toc04"><a href="">Nonlymphoid Malignancies&#9;30</a>8</p>
			<p class="fm-only_fm-toc04"><a href="">Metastatic Tumors&#9;3</a>09</p>
			<p class="fm-only_fm-toc04"><a href="">Bilateral Diffuse Uveal Melanocytic Proliferation&#9;3</a>09</p>
			<p class="fm-only_fm-toc03"><a href="">Nonneoplastic Masquerade Syndromes&#9;31</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Retinitis Pigmentosa&#9;310</a></p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Ischemic Syndrome&#9;31</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Chronic Peripheral Rhegmatogenous Ret&#173;i&#173;nal Detachment&#9;31</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Intraocular Foreign Bodies&#9;31</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Pigment Dispersion Syndrome&#9;31</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Other Syndromes&#9;31</a>1</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">1</span></a><span class="fm-toc02--num-">4&#9;</span>Complications of Uveitis<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>313</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;31</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Calcific Band Keratopathy&#9;31</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Cataracts&#9;31</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Management&#9;31</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Complications&#9;31</a>6</p>
			<p class="fm-only_fm-toc03"><a href="">Glaucoma&#9;31</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Uveitic Ocular Hypertension&#9;31</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Uveitic Glaucoma&#9;31</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Corticosteroid-&#173;Induced Ocular Hypertension and Glaucoma&#9;3</a>19</p>
			<p class="fm-only_fm-toc04"><a href="">Management&#9;31</a>9</p>
			<p class="fm-only_fm-toc03"><a href="">Hypotony&#9;32</a>1</p>
			<p class="fm-only_fm-toc03"><a href="">Uveitic Macular Edema&#9;32</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Treatment&#9;32</a>2</p>
			<p class="fm-only_fm-toc03"><a href="">Epiret&#173;i&#173;nal Membrane and Macular Hole&#9;32</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Vitreous Opacification and Vitritis&#9;32</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">Rhegmatogenous Ret&#173;i&#173;nal Detachment&#9;32</a>4</p>
			<p class="fm-only_fm-toc03"><a href="">Ret&#173;i&#173;nal and Choroidal Neovascularization&#9;32</a>4</p>
			<p class="fm-only_fm-toc03"><a href="">Vision Rehabilitation&#9;32</a>5</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;</span><a href=""><span class="fm-toc02--num-">1</span></a><span class="fm-toc02--num-">5&#9;</span>Ocular Involvement in AIDS<a href=""><span class="fm-toc--leader-dots-">&#9;</span></a>327</p>
			<p class="fm-only_fm-toc03"><a href="">Highlights&#9;32</a>7</p>
			<p class="fm-only_fm-toc03"><a href="">Ophthalmic Manifestations&#9;32</a>7</p>
			<p class="fm-only_fm-toc04"><a href="">Cytomegalovirus Retinitis&#9;3</a>28</p>
			<p class="fm-only_fm-toc04"><a href="">Necrotizing Herpetic Retinitis&#9;33</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Toxoplasmic Retinochoroiditis&#9;33</a>0</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Syphilis&#9;33</a>1</p>
			<p class="fm-only_fm-toc04"><a href="">Multifocal Choroiditis and Systemic Dissemination&#9;33</a>2</p>
			<p class="fm-only_fm-toc04"><a href=""><span class="CharOverride-9">Pneumocystis jirovecii</span> Choroiditis&#9;33</a>2</p>
			<p class="fm-only_fm-toc04"><a href=""><span class="CharOverride-9">Cryptococcus neoformans</span> Choroiditis&#9;33</a>3</p>
			<p class="fm-only_fm-toc03"><a href="">External Eye Manifestations&#9;33</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Ocular Adnexal Kaposi Sarcoma&#9;33</a>3</p>
			<p class="fm-only_fm-toc04"><a href="">Molluscum Contagiosum&#9;33</a>4</p>
			<p class="fm-only_fm-toc04"><a href="">Herpes Zoster&#9;33</a>4</p>
			<p class="fm-only_fm-toc04">Other Infections&#9;334</p>
			<p class="fm-only_fm-toc03 ParaOverride-18"><a href="">Appendix</a>: <a href="">Diagnostic Survey for Uveitis&#9;3</a>35</p>
			<p class="fm-only_fm-toc03">Basic Texts&#9;339</p>
			<p class="fm-only_fm-toc03">Related Academy Materials&#9;341</p>
			<p class="fm-only_fm-toc03">Requesting Continuing Medical Education Credit&#9;343</p>
			<p class="fm-only_fm-toc03">Study Questions&#9;345</p>
			<p class="fm-only_fm-toc03">Answer Sheet for Section 9 Study Questions&#9;353</p>
			<p class="fm-only_fm-toc03">Answers&#9;354</p>
			<p class="fm-only_fm-toc03">Index&#9;361</p>
		</div>
		<div id="_idContainer020" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet CharOverride-14"></span> Contents</p>
		</div>
		<div id="_idContainer021" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhr">Contents <span class="rh-bullet CharOverride-14">d</span>  </p>
		</div>
		<div id="_idContainer022" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet CharOverride-14"></span> Contents</p>
		</div>
		<div id="_idContainer023" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhr">Contents <span class="rh-bullet CharOverride-14">d</span>  </p>
		</div>
		<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet CharOverride-14"></span> Contents</p>
		</div>
		<div id="_idContainer025" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet CharOverride-14"></span> General Introduction</p>
		</div>
		<div id="_idContainer026" class="Basic-Text-Frame">
			<p class="fm-only_fm-h2_QR">Videos</p>
		</div>
		<div id="_idContainer027" class="Basic-Text-Frame">
			<p class="fm-only_fm-h2_QR">Activity</p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer028" class="_idGenObjectStyleOverride-4">
			</div>
		</div>
		<div id="_idContainer029" class="Basic-Text-Frame">
			<p class="fm-only_fm-objectives-title"><span class="CharOverride-15">Objectives</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer030" class="Basic-Graphics-Frame _idGenObjectStyleOverride-5">
			</div>
		</div>
		<div id="_idContainer031" class="Basic-Text-Frame">
			<p class="fm-only_fm-objectives-text ParaOverride-19">Upon completion of BCSC Section&#160;9, <span class="fm-objectives-text_italic">Uveitis and Ocular Inflammation,</span> the reader should be able to</p>
			<ul>
				<li class="fm-only_fm-objectives-bullet-list-first">describe the immunologic and infectious mechanisms involved in the development of and complications from uveitis and related inflammatory conditions, including acquired immunodeficiency syndrome</li>
				<li class="fm-only_fm-objectives-bullet-list-mid">identify general and specific pathophysiologic pro&#173;cesses in acute and chronic intraocular inflammation that affect the structure and function of the uvea, lens, intraocular spaces, ret&#173;ina, and other tissues</li>
				<li class="fm-only_fm-objectives-bullet-list-mid">differentiate infectious from noninfectious uveitic entities</li>
				<li class="fm-only_fm-objectives-bullet-list-mid">formulate appropriate differential diagnoses for ocular inflammatory disorders and Identify systemic associations or Implications</li>
				<li class="fm-only_fm-objectives-bullet-list-mid">based on the differential diagnosis, choose examination techniques and appropriate ancillary studies to differentiate infectious from noninfectious &#173;causes</li>
				<li class="fm-only_fm-objectives-bullet-list-mid">describe the princi&#173;ples of medical and surgical management of infectious and noninfectious uveitis and related intraocular inflammation, including indications for, adverse effects of, and monitoring of immunosuppressive drugs</li>
				<li class="fm-only_fm-objectives-bullet-list-mid">describe the structural complications of uveitis, their prevention, and their treatment</li>
				<li class="fm-only_fm-objectives-bullet-list-last">describe the main princi&#173;ples for differentiating masquerade syndromes from true uveitis and increasing clinical suspicion for &#173;these syndromes</li>
			</ul>
		</div>
	</body>
</html>
